Survival and complications of viral cirrhosis after suppressing the aetiological factor
Keywords:
Cirrhosis, hepatitis B virus, hepatitis C virus, removal aetiological factor, complications, survivalAbstract
Introduction: Aetiological factor removal in viral liver cirrhosis (LC) reduces complications and increases survival in some patients, a finding that is not consistent across studies.
Objective: To determine the incidence of complications and survival in patients with viral cirrhosis when suppressing the etiological factor.
Methods: Historical cohort in cirrhotics of viral aetiology B (HBV) and C (HCV), at the Institute of Gastroenterology included between 2005-2012, the follow-up until December 2019. Stratified according to reception of treatment and sustained virological response (SVR), demographic and laboratory variables, comorbidities, complications and survival were analyzed. The cumulative incidence of complications and survival were analyzed using Kaplan-Meier and predictive factors by Cox regression.
Results: Among 221 patients, the median age was 58 years, 56.6% female and 85.5% with HCV. After 10 years of follow-up, 113 (51.1%) received antiviral treatment, 23.9% achieved SVR, higher in HBV vs HCV (44% vs 18.2%). Antiviral treatment did not modify the incidence of complications, while HCV was associated with greater complications [HR: 1.51 (95% CI: 1.03-2.23)]. 81 deaths recorded (46.9%), survival was higher in the group that received antiviral treatment (p=0.028), comorbidities implied lower survival [HR: 1.52 (95% CI: 1.00-2.27)]. Viral suppression was not related to the development of complications (p= 0.681) or survival (p=0.062).
Conclusions: Although the survival was higher in patients who received antiviral treatment, the suppression of the etiological factor did not impact the development of complications or survival.
Downloads
References
Minor SE, Eliacin I, Kashan S, Whisenant EB. Cirrhosis complications: Keeping them under control [Internet]. Parsippany, NJ, USA: Mdedge.com; Jun 2015 [consultado 30 noviembre 2020]. Disponible en: https://www.mdedge.com/familymedicine/article/99900/gastroenterology/cirrhosis-complications-keeping-them-under-control
Chen T, Wong R, Wong P, Rollet-Kurhajec K, Alshaalan R, Deschenes M, et al. Occult cirrhosis diagnosed by transient elastography is a frecuent and under-monitored clinical entity. Liver Int. 2015;35(10): 2285-2293. DOI: https://doi.org/10.1111/liv.12802.
Shah A, Amarapurkar D. Natural history of Cirrhosis of Liver after First Decompensation: A Prospective Study in India. J Clin Experimental Hepatol. 2018;8(1):50-57. DOI: https://doi.org/10.1016/j.jceh.2017.06.001.
Fujiyama S, Saitoh S, Kawamura Y, Sezaki H, Hosaka T, Akuta N et al. Portal vein thrombosis in liver cirrhosis: incidence, management, and outcome. BMC Gastroenterology. 2017;17(1):112. DOI: https://doi.org/10.1186/s12876-017-0668-8.
D’Amico G, Pagliaro L, Bosch J. Pharmacological treatment of portal hypertension: an evidence-based approach. Seminars Liver Dis.1999;19(4):475-505. DOI: https://doi.org/10.1055/s-2007-1007133.
Asrani SK, Devarbhavi H, Eaton J, Kamath PS. Burden of liver diseases in the world. J Hepatol. 2019;70(1):151-7. DOI: https://doi.org/10.1016/j.jhep.2018.09.014.
World health statistics 2016: monitoring health for the SDGs, sustainable development goals. [Internet]. World Health Organization,Geneva2016[Consultado 28 septiembre 2020]. Disponible en: http://apps.who.int/iris/bitstream/10665/206498/1/9789241565264_eng.pdf?ua=1
Goldberg D, Ditah IC, Saeian K, Lalehzari M, Aronsohn A, Gorospe EC, et al. Changes in the prevalence of hepatitis C virus infection, nonalcoholic steatohepatitis, and alcoholic liver disease among patients with cirrhosis or liver failure on the waitlist for liver transplantation. Gastroenterology. 2017;152(5):1090-1099. DOI: https://doi.org/10.1053/j.gastro.2017.01.003.
Tsai M, Chen C, Hu T, Lu S, Lee C, Wang J, et al. Long-term outcomes of hepatitis B virus-related cirrhosis treated with nucleos(t)ide analogs. J Formosan Med Ass. 2017;116(7):512-521. DOI: https://doi.org/10.1016/j.jfma.2016.08.006.
Wong R, Aguilar M, Cheung R, Perumpail R, Harrison S, Younossi Z, et al. Nonalcoholic Steatohepatitis is the second leading etiology if liver disease among adults awaiting liver transplantation in the United States. Gastroenterology. 2015;148(3):547–555. DOI: https://doi.org/10.1053/j.gastro.2014.11.039.
Dirección de registros médicos y estadísticas de salud. Anuario Estadístico de Salud 2021[Internet]. La Habana: MINSAP; 2021[Consultado10diciembre 2022]. Disponible en: http://www.sld.cu/sitios/dne/
Vilar E, Sánchez Y, Calzadilla L, Torres A, Martínez Y, Arus E et al. The natural history of compensated HCV-related cirrhosis: A prospective long term study. J Hepatol. 2013;58(3):434–444. DOI: https://doi.org/10.1016/j.jhep.2012.10.023.
Angeli P, Bernardi M, Villanueva C, Francoz C, Mookerjee R, Trebicka J et al. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J Hepatol. 2018;69(2):406-460. DOI: https://doi.org/10.1016/j.jhep.2018.03.024.
Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009;49(4):1335-1374. DOI: https://doi.org/10.1002/hep.22759.
AASLD-IDSA HCV Guidance Panel. Hepatitis C guidance 2018 update: AASLD-IDSA recommendations for testing, managing, and treating hepatitis C virus infection. Clinical Infect Dis. 2018;67(10):1477-1492. DOI: https://doi.org/10.1093/cid/ciy585.
European Association for The Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol.2017;67(2), 370-398. DOI: https://doi.org/10.1016/j.jhep.2017.03.021.
An C, Rakhmonova G, Choi J-Y, Kim M-J. Liver imaging reporting and data system (LI-RADS) version 2014: understanding and application of the diagnostic algorithm. Clin Molecular Hepatol. 2016; 22(2):296. DOI: https://doi.org/10.3350/cmh.2016.0028.
Weissenborn, Karin. Hepatic encephalopathy: definition, clinical grading and diagnostic principles. Drugs. 2019;79(1): 5-9. DOI: https://doi.org/10.1007/s40265-018-1018-z.
World Medical A. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191-4. DOI: https://doi.org/10.1001/jama.2013.281053.
Lorenzo FYM, Ávila MH, González JAG, Sarmiento AM, Montalvo DS, Rodríguez DJ. Relación clínico-evolutiva de pacientes con cirrosis hepática y várices esofágicas tratados con propranolol para la prevención de la hemorragia digestiva. MediCiego [Internet]. 2017[Consultado 22 septiembre 2021]; 22(S1), 1-Archivos Cubanos de Gastroenterología. 2021;2(2):e58Esta obra está bajo una licencia https://creativecommons.org/licenses/by-nc/4.0/deed.es_ES12. Disponible en: https://www.medigraphic.com/cgi-bin/new/resumen.cgi?IDARTICULO=70810
Castellanos M, López Y, Sánchez Y, Lazo S, Hernández J. Particularidades del carcinoma hepatocelular en los pacientes con cirrosis hepática. Rev Cubana Med [Internet]. 2011[Consultado 22 septiembre 2021];50(1):57-69.Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0034-75232011000100006
Asrani S, Kamath P. Natural History of Cirrhosis. Curr Gastroenterol Rep. 2013;15(2):308. DOI: https://doi.org/10.1007/s11894-012-0308-y.
García B, González F, Mateos R, Moreno O. Cirrosis Hepática. Medicine [Internet]. 2012[Consultado 22octubre 2021]; 11(11):625-630.Disponible en: https://www.sciencedirect.com/science/article/pii/S0304541212703591
Bruno, S., Di Marco, V., Iavarone, M., Roffi, L., Crosignani, A., Calvaruso, V., et al. Survival of patients with HCV cirrhosis and sustained virologic response is similar to the general population. J Hepatol. 2016;64(6):1217-1223. DOI: https://doi.org/10.1016/j.jhep.2016.01.034.
Nahon P, Bourcier V, Layese R, Audureau E, Cagnot C, Marcellin P, et al. Erradication of Hepatitis C Virus Infection in Patients with Cirrhosis Reduces Risk of Liver and Non-Liver Complications. Gastroenterology. 2017;(157):142-156. DOI: https://doi.org/10.1053/j.gastro.2016.09.009.
Dresch K, Mattos A, Tovo C, Onofrio F, Casagrande L, Feltrin A, et al. Impact Of The Pegylated-Interferon And Ribavirin Therapy On The Treatment-Related Mortality Of Patients With Cirrhosis Due To Hepatitis C Virus. Rev Inst Med Trop São Paulo. 2016;58:37. DOI: https://doi.org/10.1590/S1678-9946201658037.
Jang J, Choi J, Kim Y, Yoo J, Woo H, Choi S, et al. Effects of Virologic Response to Treatment on Short-and Long-term Outcomes of Patients With Chronic Hepatitis B Virus Infection and Decompensated Cirrhosis. Clinical Gastroenterol Hepatol. 2018;16(12):1954-1963.e3. DOI: https://doi.org/10.1016/j.cgh.2018.04.063.
Hallager S, Ladelund S, Christensen P, SkalshøiKjær M, Thorup Roege B, Grønbæk K et al. Liver-related morbidity and mortality in patients with chronic hepatitis C and cirrhosis with and without sustained virologic response. Clin Epidemiol. 2017;9:501-516. DOI: https://doi.org/10.2147/CLEP.S132072.
Dorta Z,Castellanos M, Nodarse H, Arus E, Perez F, Gonzalez L. Tolerancia del tratamiento con interferón estándar y ribavirina en pacientes cirróticos por virus de la hepatitis C. Rev cubana med [Internet]. 2010 Jun [Consultado7Marzo2020]; 49 (2). Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0034-75232010000200001Ing=es
González MS, Gallegos JF. Interferón alfa y fibrosis hepática en pacientes con daño crónico por el virus de hepatitis C. Rev Gastroenterol Mex [Internet]. 2003[Consultado 7 Marzo 2020];68 (3):239-244. Disponible en: https://www.researchgate.net/profile/Ma-Gonzalez-Huezo/publication/8936665_Interferon-alpha_and_liver_fibrosis_in_patients_with_chronic_damage_due_to_hepatitis_C_virus/links/5b15d6bc0f7e9bda0ffe02ba/Interferon-alpha-and-liver-fibrosis-in-patients-with-chronic-damage-due-to-hepatitis-C-virus.pdf
Hung H, Liao H, Chen S, Tsao S, Lee Y. Maintenance interferon therapyin chronic hepatitis C patients who failed initial antiviral therapy. Medicine. 2019;98(19):e15563. DOI: https://doi.org/10.1097/MD.0000000000015563.
Ma Y J, Du LY, Yan L B, Liao J, Cheng X, Xie WW, et al. Long-term follow-up of HCV patients with sustained virological response after treatment with pegylated interferon plus ribavirin. Hepatobiliary Pancreat Dis Int. 2021;20(2):137-141. DOI: https://doi.org/10.1016/j.hbpd.2020.02.004.
Bae J, Sinn DH, Kang W, Gwak GY, Choi MS, Paik YH, et al. Validation of the Baveno VI and the expanded Baveno VI criteria to identify patients who could avoid screening endoscopy. Liver Int. 2018,38(8):1442-1448. DOI: https://doi.org/10.1111/liv.13732
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Archivos Cubanos de Gastroenterolog?a
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
La revista reconoce a las personas que firman como autores siempre y cuando estos cumplan con los criterios establecidos universalmente para los autores de los art?culos cient?ficos. Regularmente se solicitar? a los autores de art?culos originales, env?en la declaraci?n de autor?a firmada por cada uno de ellos y donde se explique su rol dentro de la investigaci?n. El comit? editorial se reserva el derecho de aceptar determinados autores en relaci?n con el rol declarado y la envergadura de la investigaci?n.
Esta revista protege los Derechos de autor desde el mismo momento en que se realiza el env?o. Sin embargo, cede parte de los derechos patrimoniales de autor al exhibir una licencia Creative Commons 4.0 (cc-by-nc), que permite el uso de la obra para compartir (copiar y redistribuir el material en cualquier medio o formato) y adaptar (remezclar, transformar y construir a partir del material) siempre y cuando se haga menci?n exclusiva a la publicaci?n en la revista como fuente primaria. ?Sin embargo, no podr? comercializar con ella.
?
